NeoPEX Pre-Mixed Obturation Paste
NuSmile, Ltd. · Decision date Sep 4, 2026
What did the FDA decide?
On September 4, 2026, FDA recorded a substantial equivalence determination (SESE) for NeoPEX™ Pre-Mixed Obturation Paste, submitted by NuSmile, Ltd. under K253909. The device is a non-sterile, premixed hydraulic calcium silicate paste containing calcium hydroxide, supplied in a prefilled syringe with disposable dispensing tips; the summary states it hardens in moisture, creates an alkaline environment, releases calcium, and is radiopaque. It is classified under 21 CFR 872.3820 with product codes KIF and EJK.
The submission lists nRoot SP (K250710) as primary predicate, with nRoot BP (K251465), MTA 2.3 (K181917) and UltraCal XS (K211905) as reference devices. The summary reports similar form, delivery, composition, setting per ISO 6876, calcium release and pH above 11, and states no clinical studies were required. SE is a clearance, not a PMA approval. The source does not provide the full decision letter text, so any conditions beyond the quoted QMSR reminder remain unknown.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Dental
- Decision date
- Sep 4, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K253909
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- NuSmile, Ltd.
- Product code
- KIF
- Decision code
- SESE
- Decision date
- Sep 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Resin, Root Canal Filling.
- Applicant
- NuSmile, Ltd.
- Product code
- KIF
- FDA device class
- 2
FDA decision timeline
K253909 received
Application receipt date recorded by FDA.
K253909 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code KIF
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
BCS Bioceramic SealerK262478 | BCS Device Pte., Ltd. | 510(k) clearance | Oct 16, 2026 | FDA |
Vioseal XK262050 | Spident Co., Ltd. | 510(k) clearance | Sep 11, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
NuSmile, Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Houston, TX
Sources and methodology
- Original FDA record: K253909
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
